Plasma protein profiling by mass spectrometry for cancer diagnosis: Opportunities and limitations

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 963-965

  Diamandis, Eleftherios P ^a   Van Der Merwe, Da Elene ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA FETOPROTEIN; APOLIPOPROTEIN A1; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; HAPTOGLOBIN; INTER ALPHA TRYPSIN INHIBITOR; PREALBUMIN; PROSTATE SPECIFIC ANTIGEN; SERUM AMYLOID A; TUMOR MARKER; VITAMIN D BINDING PROTEIN;

BIOINFORMATICS; BLOOD ANALYSIS; CANCER DIAGNOSIS; CEREBROSPINAL FLUID ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DNA LIBRARY; DNA MICROARRAY; EDITORIAL; GENE EXPRESSION; HUMAN; HUMAN GENOME; LABORATORY DIAGNOSIS; MASS SPECTROMETRY; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEIN SECRETION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEROLOGY; URINALYSIS;

BLOOD PROTEINS; HUMANS; NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 12944272015     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nature Rev Cancer 2003;3:243-52.
2. Welsh JB, Sapinoso LM, Kern SG, et al. Large-sscale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. PNAS 2003;100:3410-5.
3. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003;63:2223-7.
4. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001;98:1176-81.
5. Menon U, Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002;16:469-82.
6. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
7. Petricoin EF III, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-5.
8. Isaaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD. SELDI-TOF MS for diagnostic proteomics. Anal Chem 2003;75:149-55A.
9. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol Cell Proteomics 2004;3:367-78.
10. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.
11. Diamandis EP. Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin Chem 2003;49: 1271-8.
12. Sorace JM, Zhan M. A data review and reassessment of ovarian cancer serum proteomic profiling. B.M.C. Bioinformatics 2003;4:24 [http://www.biomedcentral. eom/1471-2105/4/24].
13. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing data sets from different experiments. Bioinformatics Adv Access 1-9, Oxford University Press 2004.
14. Check E. Running before we can walk? Nature 2004;429:496-7.
15. Diamandis EP. Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal carcinoma. Clin Cancer Res 2004;10:5293.
16. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res. In press.
17. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
18. Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004;76:1560-70.
19. Ransohoff DF. Evaluating discovery-based research: When biologic reasoning cannot work. Gastroenterol 2004;127:1028.
20. Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization (SELDI) and neural-network analysis: Identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971-83.
21. Radhakrishna S, Tirumalai S, Chan KC, et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096-103.
22. Liotta LA, Ferrari M, Petricoin E. Written in blood. Nature 2003;425:905.
23. Burtis CA, Ashwood ER. Tietz textbook of clinical chemistry. 2nd ed. Philadelphia: W.B. Saunders Co.; 1994.
24. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-11.
25. Hlavaty JJ, Partin AW, Shue MJ, et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003;61:1261-5.
26. Cho WSC, Yip TTC, Yip C, et al. Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52.